

# Ilkka Liikanen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2715232/publications.pdf>

Version: 2024-02-01

23  
papers

875  
citations

567281

15  
h-index

677142

22  
g-index

23  
all docs

23  
docs citations

23  
times ranked

1163  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncolytic adenovirus decreases the proportion of TIM-3 <sup>+</sup> subset of tumor-infiltrating CD8 <sup>+</sup> T cells with correlation to improved survival in patients with cancer. , 2022, 10, e003490.		10
2	Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+ T cells. Journal of Clinical Investigation, 2021, 131, .	8.2	66
3	Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy. Molecular Therapy - Oncolytics, 2018, 9, 41-50.	4.4	8
4	Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients. Oncotarget, 2018, 9, 6320-6335.	1.8	10
5	Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy. Molecular Therapy, 2016, 24, 1323-1332.	8.2	28
6	Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer. Molecular Cancer Therapeutics, 2016, 15, 2259-2269.	4.1	31
7	Fate of fenestration in children treated with fontan operation. Catheterization and Cardiovascular Interventions, 2016, 87, E233-9.	1.7	6
8	Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus. Molecular Therapy, 2016, 24, 175-183.	8.2	26
9	Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer. OncoImmunology, 2016, 5, e1078057.	4.6	29
10	Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: results <i>in vitro</i> , in rodents and in humans. International Journal of Cancer, 2015, 137, 1775-1783.	5.1	41
11	T-cell Subsets in Peripheral Blood and Tumors of Patients Treated With Oncolytic Adenoviruses. Molecular Therapy, 2015, 23, 964-973.	8.2	11
12	Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy. OncoImmunology, 2015, 4, e989771.	4.6	47
13	Caseâ€“Control Estimation of the Impact of Oncolytic Adenovirus on the Survival of Patients With Refractory Solid Tumors. Molecular Therapy, 2015, 23, 321-329.	8.2	14
14	Immunological data from cancer patients treated with Ad5/3-E2F- $\beta$ 24-GMCSF suggests utility for tumor immunotherapy. Oncotarget, 2015, 6, 4467-4481.	1.8	63
15	Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. International Journal of Cancer, 2014, 135, 720-730.	5.1	36
16	Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment. Journal of Translational Medicine, 2013, 11, 193.	4.4	13
17	Oncolytic Adenovirus With Temozolomide Induces Autophagy and Antitumor Immune Responses in Cancer Patients. Molecular Therapy, 2013, 21, 1212-1223.	8.2	146
18	Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSFâ€“Coding Oncolytic Adenovirus. Clinical Cancer Research, 2013, 19, 2734-2744.	7.0	150

#	ARTICLE	IF	CITATIONS
19	Verapamil Results in Increased Blood Levels of Oncolytic Adenovirus in Treatment of Patients With Advanced Cancer. <i>Molecular Therapy</i> , 2012, 20, 221-229.	8.2	33
20	Induction of Interferon Pathways Mediates In Vivo Resistance to Oncolytic Adenovirus. <i>Molecular Therapy</i> , 2011, 19, 1858-1866.	8.2	42
21	Targeted Chemotherapy for Head and Neck Cancer with a Chimeric Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1. <i>Clinical Cancer Research</i> , 2010, 16, 2540-2549.	7.0	37
22	Adenoviral E4orf3 and E4orf6 Proteins, But Not E1B55K, Increase Killing of Cancer Cells by Radiotherapy in vivo. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1201-1209.	0.8	3
23	Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures. <i>European Journal of Cancer</i> , 2010, 46, 625-635.	2.8	25